HSBC Reverses Stance, Issues Bullish Call on Novo Nordisk Shares
Published on 10/03/2025 at 18:54 | Redaktion boerse-global.de
A dramatic shift in analyst sentiment has injected fresh momentum into Novo Nordisk’s stock this week, breaking a prolonged period of sideways trading. The catalyst was a significant upgrade from HSBC, potentially signaling the beginning of a comprehensive reassessment of the Danish pharmaceutical giant’s development pipeline and market strategy.
In a notable reversal, Rajesh Kumar of HSBC Global Research upgraded his rating on Novo Nordisk to “Buy,” accompanied by a substantial price target of 70 US dollars. This move represents a complete about-face from his late-July position, when he had downgraded the stock to “Hold.”
The analyst’s change of heart stems from Novo Nordisk’s enhanced strategic focus on reimbursable medical treatments and establishing... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
